local_hospital

Region Soermland

Address
lock Available on a paid plan

Diseases [C] - Bacterial Infections and Mycoses

The research team at Region Soermland is evaluating topical antimicrobial agents to speed healing of infected wounds, focusing on patients with diabetic foot ulcer. The goal is to determine which local treatments achieve faster closure and reduce the need for hospital care.

  • Topical wound antiseptics
  • Infection control in chronic ulcers
  • Outpatient wound management
  • Healing time assessment

Results are expected to guide community‑based protocols for managing complex skin infections.

Diseases [C] - Cardiovascular Diseases

Investigators are testing whether adding spironolactone or eplerenone to standard therapy can lower hospitalization and cardiovascular death in patients with heart failure with preserved ejection fraction. The study uses a registry‑based design to capture real‑world outcomes.

  • Mineralocorticoid receptor blockade
  • HFpEF patient outcomes
  • Registry‑based randomized trial
  • Cardiovascular event reduction

Findings may reshape treatment guidelines for this growing heart‑failure subgroup.

Diseases [C] - Female Urogenital Diseases and Pregnancy Complications

A comparison is being made between outpatient and inpatient approaches to labour induction to verify safety and effectiveness for expectant mothers. The trial seeks to show that care outside the hospital can be just as reliable.

  • Outpatient induction protocols
  • Maternal and fetal safety metrics
  • Healthcare resource utilization
  • Patient satisfaction

Conducted at Vårdcentralen Centrum Flen, the work could inform national obstetric guidelines.

Diseases [C] - Neoplasms

The centre is assessing whether a coordinated strategy of HPV vaccination and systematic HPV screening can accelerate the elimination of infection and lower rates of cervical cancer among young women.

  • Population‑level vaccination impact
  • Cervical cancer prevention
  • Screening program integration
  • Epidemiological outcomes

The initiative aligns with Sweden’s national cervical screening program and targets women aged 23‑25.

Diseases [C] - Nutritional and Metabolic Diseases

Researchers are comparing early use of a SGLT2‑inhibitor with the traditional metformin regimen to see which better preserves metabolic health in newly diagnosed type 2 diabetes patients.

  • First‑line diabetes therapy
  • Progression‑free survival
  • Metabolic control metrics
  • Long‑term complication risk

Outcomes could influence prescribing practices for early diabetes management.

Diseases [C] - Skin and Connective Tissue Diseases

The trial evaluates two moisturising creams to determine which more effectively prevents relapse of atopic dermatitis, aiming to improve long‑term skin health for patients.

  • Moisturiser comparative effectiveness
  • Eczema relapse timing
  • Patient‑reported symptom relief
  • Daily skin‑care strategies

Findings will support evidence‑based recommendations for routine eczema maintenance.

Psychiatry and Psychology [F] - Mental Disorders

An innovative study is testing whether the immunomodulatory drug rituximab can improve symptoms in adults with schizophrenia spectrum disorder, compared with placebo.

  • Immunotherapy in psychiatry
  • Symptom reduction metrics
  • Placebo‑controlled design
  • Neuroinflammatory mechanisms

Positive results could open new therapeutic avenues for resistant psychotic conditions.

Site Overview

assignment
9
connected trials
corporate_fare
10
sponsors
science
22
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
9
Total trials linked
Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 8 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
7
Sponsors (total)
10
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 188 other sites in Sweden

description
Trial volume
9
Outperforms 74% of sites
public
Therapeutic diversity
8areas
Outperforms 79% of sites
groups
Sponsor diversity
10sponsors
Outperforms 78% of sites

Therapeutic Area Benchmark — Sweden

Select a therapeutic area to compare against other sites in Sweden.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Sweden

Market Share

Country: Sweden

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Region Soermland

lock Showing 1 of 9 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Randomized Controlled Trial Comparing Dapagliflozin Propanediol and Metformin in Early Stage Type 2 Diabetes for Mortality and Vascular ComplicationsUppsala UniversityPhase IIIRecruitingAug 2024

IMP list

lock Showing 1 of 22 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Altizide1Unknown2017-11-232017-11-23

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.